Hepatitis C Treatment With Generic Sofosbuvir‐Based Regimens in Patients Undergoing Hemodialysis
Hemodialysis International · 2025
DOI: 10.1111/hdi.13198 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hemodialysis International, 2025. Verfasst von Nawal Afredj und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Department, Centre Hospitalo Universitaire Mustapha, Algiers, Algeria. Hauptthemen laut MEDLINE: Sofosbuvir, Renal Dialysis, Antiviral Agents, Hepatitis C. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Objectives
To assess the efficacy and safety of locally manufactured generic sofosbuvir‐based direct‐acting antivirals in the treatment of Hepatitis C virus (HCV) infected patients on maintenance hemodialysis. Patients and Methods We have conducted a retrospective multicenter study including patients on maintenance hemodialysis, treated with sofosbuvir‐based regimens between 01/01/2017 and 09/30/2021. Patients were treated for 12 or 24 weeks, with sofosbuvir 400 mg + ledipasvir 90 mg 3 times/week, or sofosbuvir 3 times/week + daclatasvir 60 mg/d, or sofosbuvir + daclatasvir in coformulation, 3 times/week. Sustained virological response was defined as a negative HCV RNA test 12 weeks after treatment. The occurrence of serious adverse events during treatment defines intolerance to treatment. Statistical analysis was performed using SPSS software (version 25).
Results
A total of 120 patients were treated; the mean age was 50 ± 14.17 years [18–78], 50% were men. Twenty‐two patients ( n = 22; 18.3%) were previously treated with pegylated Interferon. Genotype 1 was predominant ( n = 68; 82%). Most of the patients ( n = 53; 44.2%) had no significant fibrosis, and 24 (20%) had cirrhosis. The SVR rate was 93.3% (CI 95% [88.8; 97.8]) ( n = 112), the serious adverse events rate was 10.8% (CI 95% [0.054–0.166]) ( n = 13), including 2 deaths unrelated to direct‐acting antivirals. Early treatment discontinuation occurred in 5.8% ( n = 7), and a relapse in 0.8% ( n = 1). On multivariate analysis, risk factors for serious adverse events included advanced liver fibrosis, thrombocytopenia, hypoalbuminemia, high bilirubin level, and pre‐treatment status.
Conclusion
Locally manufactured generic sofosbuvir‐based regimens are safe and effective in maintenance hemodialysis patients. However, they should be closely monitored to manage comorbidities and complications during treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatology Department, Centre Hospitalo Universitaire Mustapha, Algiers, Algeria.
- Algiers University, Faculty of Medicine, Algeria.
- Hepato-Gastroenterology Department, Centre Hospitalo Universitaire Abdelhamid Benbadis, Constantine, Algeria.
- Constantine University, Algeria.
- Hepato-Gastroenterology Department, Centre Hospitalo Universitaire Lamine Debaghine, Algiers, Algeria.
- Epidemiology Department, Bouira, Algeria.
ORCID-Profile: Nawal Afredj
Zitieren
APA
Afredj, N., Boumendjel, M., Mahiou, H., Drir, O., Cheikh, I. O., Belimi, H., Kerbouche, R., Guessab, N., Zaidi, A., Boutra, F., Nakmouche, M., & Debzi, N. (2025). Hepatitis C Treatment With Generic Sofosbuvir‐Based Regimens in Patients Undergoing Hemodialysis. Hemodialysis International. https://doi.org/10.1111/hdi.13198
Vancouver
Afredj N, Boumendjel M, Mahiou H, Drir O, Cheikh IO, Belimi H, et al. Hepatitis C Treatment With Generic Sofosbuvir‐Based Regimens in Patients Undergoing Hemodialysis. Hemodialysis International. 2025. doi:10.1111/hdi.13198
BibTeX
@article{Afredj2025,
author = {Afredj, Nawal and Boumendjel, Mustapha and Mahiou, Hassen and Drir, Othmane and Cheikh, Ibtissem Ouled and Belimi, Hibatallah and Kerbouche, Rafik and Guessab, Nawal and Zaidi, Arezki and Boutra, Fouad and Nakmouche, M'hamed and Debzi, Nabil},
title = {Hepatitis C Treatment With Generic Sofosbuvir‐Based Regimens in Patients Undergoing Hemodialysis},
journal = {Hemodialysis International},
year = {2025},
doi = {10.1111/hdi.13198}
}
EUVIMED